7/8/2009

Excel Venture Management has unveiled a $125 million fund that it will invest in early- to late-stage life sciences companies. Aileron Therapeutics, which works on "Stapled Peptides" that home in on intracellular protein-protein interactions, is among the three firms that secured financing from the Excel Medical Fund.

Related Summaries